Title: Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.
Journal: Oncotarget 20120301
Title: Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
Journal: Journal of medicinal chemistry 20120112
Title: ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
Journal: PloS one 20120101
Title: A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Journal: Cancer chemotherapy and pharmacology 20110301
Title: Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010).
Journal: Expert opinion on therapeutic patents 20110201
Title: Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
Journal: Bioorganic & medicinal chemistry 20080801
Title: Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation.
Journal: Bioorganic & medicinal chemistry letters 20080615
Title: 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation.
Journal: Molecular cancer therapeutics 20080101
Title: Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner.
Journal: PloS one 20080101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20070601
Title: A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070401
Title: A chemostat study of Streptomyces peucetius var. caesius N47.
Journal: Applied microbiology and biotechnology 20070101
Title: Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancer.
Journal: Current opinion in investigational drugs (London, England : 2000) 20061201
Title: The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.
Journal: The Journal of laboratory and clinical medicine 20060201
Title: Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study.
Journal: British journal of cancer 20050131
Title: The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20050115
Title: Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress.
Journal: Cancer research 20040915
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20040401
Title: Estrogen receptor alpha gene haplotype is associated with radiographic osteoarthritis of the knee in elderly men and women.
Journal: Arthritis and rheumatism 20030701
Title: The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.
Journal: Molecular cancer therapeutics 20030301
Title: Enhancement of metabolic oxidative stress-induced cytotoxicity by the thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide is mediated through the ASK1-SEK1-JNK1 pathway.
Journal: Molecular pharmacology 20021201
Title: The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cells.
Journal: Carcinogenesis 20021001
Title: Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfide.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020305
Title: Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication.
Journal: Cancer research 20011001
Title: Welsh SJ, et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther. 2003 Mar;2(3):235-43.
Title: Lou M, et al. Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy. J Biol Chem. 2017 Jun 2;292(22):9136-9149.
Title: Metcalfe C, et al. Thioredoxin Inhibitors Attenuate Platelet Function and Thrombus Formation.PLoS One. 2016 Oct 7;11(10):e0163006
Title: Ramanathan RK, et al. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2109-14.
Title: Wang F, et al. Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines. Oncol Rep. 2015 Feb;33(2):967-73.
